Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3

Rhea-AI Filing Summary

Monopar Therapeutics director Nicole Sweeny filed an initial ownership report on Form 3. This filing establishes her status as an insider of the company but does not show any stock transactions, option exercises, or specific shareholdings in the provided data.

Key Terms

Form 3, insider, director

3 terms

Form 3 regulatory

"filed an initial ownership report on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider regulatory

"This filing establishes her status as an insider of the company"

director financial

"shows that Nicole Sweeny is a director and now an insider"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/30/2026 - 04:57 PM Accepted by SEC EDGAR 06/30/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sweeny Nicole

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE ILLINOIS 60091

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/22/2026

3. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Quan Vu, Attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Monopar Therapeutics (MNPR) Form 3 filing by Nicole Sweeny mean?

The Form 3 for Monopar Therapeutics (MNPR) shows that Nicole Sweeny is a director and now an insider. It is an initial ownership report and, in the provided data, does not list any specific stock or option transactions.

Does the MNPR Form 3 for Nicole Sweeny show any share purchases or sales?

No, the provided Form 3 data for Monopar Therapeutics (MNPR) shows no reported buy or sell transactions. All transaction counts and share amounts in the transaction summary are zero, indicating no trades disclosed in this filing excerpt.

What insider role does Nicole Sweeny hold at Monopar Therapeutics (MNPR)?

According to the Form 3 data, Nicole Sweeny is listed as a director of Monopar Therapeutics (MNPR). She is not flagged as an officer or a ten percent owner in the structured information provided with this filing.

Does the Monopar Therapeutics Form 3 include any derivative securities information?

No, the derivativeSummary section in the Monopar Therapeutics (MNPR) Form 3 data is empty. This means the excerpt does not report any options, warrants, or other derivative positions for Nicole Sweeny in this particular filing snapshot.

Are there any gifts or tax-withholding transactions in the MNPR Form 3 data?

No, the transaction summary in the Monopar Therapeutics (MNPR) Form 3 shows zero gift transactions and zero tax-withholding entries. All related share counts are listed as zero in the structured summary fields provided.